Third cohort dose is one million CAR positive cells; ten times higher than the first cohort dose . SAN JOSE, Calif., Nov. 18, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" ...

Novotech, the global full-service clinical CRO, has published a new report, Small Cell Lung Cancer: Global Clinical Trial ...

A simplified imaging protocol using just five views still had good accuracy with a median AUROC of 0.85 and normalized mean ...

For patients with diabetes, a systolic target of 120 mm Hg led to a significant reduction in CV events in BPROADS, mirroring ...

Good afternoon, and welcome to Fractyl Health's Third Quarter Financial Results and Business Updates Call. As a reminder, this conference call is being recorded. [Operator Instructions]. I will now ...

This roundup offers a look at the latest insights from the clinicians and researchers investigating chronic obstructive pulmonary disease and asthma.

Top-line data for its phase 2b trial studying GH001 is expected either in the fourth quarter of 2024 or the first quarter of ...

The University of Texas Health Science Center at San Antonio (UT Health San Antonio) ranks at the top 5% of universities in the world for clinical medicine, and in the top 12% of universities overall ...

Ipsen to present new data on elafibranor at The Liver Meeting® 2024Launch of Iqirvo® (elafibranor)1 on track with ...

Positive long-term extension data highlighting the differentiated profile of deucrictibant for the prevention and treatment of HAE attacks ...

Establishing growing body of preclinical data evaluating the DNase-based oncology platform across a number of high-value ...